logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
A

Aditya Bardia

alyssum therapeutics inc

86H-index
1.1KPaper Count
3.8WCitation Count
Published Papers 348
Publication Date
logo
Activating a B cell immune response regresses immunologically cold tumours
errNature Nanotechnology
IF34.9
err2026-06-12
err0
PREAI
errHeena Aggarwal; Nimish Gupta; Aniruddha Sengupta; Arindam Sarkar; Sanghamitra Mylavarapu; Ivan S. Pires; Tanmoy Saha; Binayak Sarkar; Ashish Kulkarni; Vinay S. Mahajan; Lipika Goyal; Aditya Bardia; Richard Fahrner; Ermanno Gherardi; Raghunath Mashelkar; Patrick Soon-Shiong; Hae Lin Jang; Shiladitya Sengupta
errShare
errSave
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study
errAnnals of Oncology
IF65.4
err2025-12-23
err0
PREAI
errB. Pistilli; K. Jhaveri; S.-A. Im; S. Pernas; M. De Laurentiis; S. Wang; N.Martínez Jañez; G. Borges; D.W. Cescon; M. Hattori; Y.-S. Lu; E. Hamilton; J. Tsurutani; K. Kalinsky; P.E.Rubini Liedke; D. Carroll; S. Khan; H.S. Rugo; B. Xu; A. Bardia
errShare
errSave
Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis
errTargeted Oncology
IF4
err2025-11-12
err0
errOAAI
errMallika Lala; Aditya Bardia; Antonio Calles; Romano Danesi; Tomoko Freshwater; Jane A. Healy; Roy S. Herbst
errShare
errSave
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis
errnpj Breast Cancer
IF7.6
err2025-08-16
err0
errOAAI
errLetizia Pontolillo; Andrew A. Davis; Lorenzo Gerratana; Arielle J. Medford; Judy Wang; Eleonora Nicolo’; Katherine Clifton; Marko Velimirovic; Surbhi Warrior; Emily Podany; Eleni Andreopoulou; Mara Serena Serafini; Laura Munoz-Arcos; Elisabetta Molteni; Marla Lipsyc-Sharf; Caterina Gianni; Nadia Bayou; Charles S. Dai; Diana Giannarelli; Emilio Bria; Cynthia X. Ma; Aditya Bardia; Carolina Reduzzi; Massimo Cristofanilli
errShare
errSave
US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan
errSupportive Care in Cancer
IF3
err2025-08-05
err0
errOAAI
errHope Rugo; Aditya Bardia; Debora S. Bruno; Vinicius Ernani; Erika Hamilton; Rebecca Heist; Komal Jhaveri; Benjamin Levy; Aaron Lisberg; Joyce O’Shaughnessy; Jacob Sands; Alexander Spira; Sara Tolaney; Nathaniel S. Treister; Cecile Matthews; Melissa Johnson
errShare
errSave
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer
erreBioMedicine
IF10.8
err2025-06-27
err0
PREAI
errMaxwell R. Lloyd; Rosario Chica-Parrado; Caroline M. Weipert; Todd C. Knepper; Emily L. Podany; Fabiana Napolitano; Dan Ye; Chang-Ching Lin; Yasuaki Uemoto; Jiemin Liao; Claire Wegrzyn; Christine M. Walko; Lianne Y. Ryan; Jennifer C. Keenan; Arielle J. Medford; Shiyuan A. Liu; Gerburg M. Wulf; Katherine K. Clifton; Cynthia X. Ma; Hyo S. Han; Nicole Zhang; Leif W. Ellisen; Aditya Bardia; Carlos L. Arteaga; Ariella B. Hanker; Seth A. Wander
errShare
errSave
Role of immunotherapy in early breast cancer: past, present, and future
errTargeted Oncology
IF4
err2025-06-20
err0
PREAI
errKarissa Britten; Aditya Bardia; Nicholas McAndrew
errShare
errSave
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study
errESMO Open
IF8.3
err2025-06-01
err0
errOAAI
errL. García-Estévez; A. Bardia; H.S. Rugo; L.A. Carey; V.C. Diéras; S. Loibl; M. Piccart; L. Gianni; K. Kalinsky; J. O’Shaughnessy; S.A. Hurvitz; E. Harting; T. Valdez; S. Phan; C. Lai; J. Cortés
errShare
errSave
Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists
errbreast
IF0
err2025-05-03
err0
errOAAI
errHope S. Rugo; Aditya Bardia; William J. Gradishar; Erika P. Hamilton; Sara A. Hurvitz; Komal Jhaveri; Reshma Mahtani; Sara M. Tolaney
errShare
errSave
Brain metastases in patients with metastatic breast cancer and BRCA1/2 mutations in cell-free DNA
errBREAST CANCER RESEARCH AND TREATMENT
IF3
err2025-04-25
err0
PREAI
errVidula, Neelima; Blouch, Erica; Hesler, Katherine; Niemierko, Andrzej; Bardia, Aditya
errShare
errSave
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium
errClinical Breast Cancer
IF2.5
err2025-04-08
err0
PREAI
errKomal Jhaveri; Carey K. Anders; Aditya Bardia; Manali Bhave; A. Jo Chien; Ian Krop; Tiffany A. Traina; Yara Abdou; Reva Basho; Alison K. Conlin; Francisco J. Esteva; Kevin R. Fox; Vijayakrishna Gadi; Peter A. Kaufman; Anya Litvak; Cynthia X. Ma; Eleftherios P. Mamounas; Heather McArthur; Kelly McCann; Zahi Mitri; Rebecca Shatsky; Melinda Telli; Mylin A. Torres; Kevin Kalinsky
errShare
errSave
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies
errNPJ BREAST CANCER
IF7.6
err2025-03-11
err0
errOAAI
errBar, Yael; Fell, Geoffrey; Dedeoglu, Aylin; Moffett, Natalie; Vidula, Neelima; Spring, Laura; Wander, Seth A.; Bardia, Aditya; Ko, Naomi; Moy, Beverly; Ellisen, Leif W.; Isakoff, Steven J.
errShare
errSave
Biology, care, and outcomes of gestational breast cancers: a review
errBREAST CANCER RESEARCH AND TREATMENT
IF3
err2025-03-01
err0
errOAAI
errDuggirala, Niharika; Zhang, Shiliang; Master, Aashini; Rao, Rashmi; Kapoor, Nimmi S.; Bardia, Aditya; Lipsyc-Sharf, Marla
errShare
errSave
Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer
errJAMA NETWORK OPEN
IF9.7
err2025-02-26
err1
errOAAI
errPodany, Emily L.; Foffano, Lorenzo; Gerratana, Lorenzo; Medford, Arielle J.; Clifton, Katherine; Tapiavala, Shaili; Velimirovic, Marko; Lipsyc-Sharf, Marla; Reduzzi, Carolina; Bubie, Adrian; Putur, Annika; Ademuyiwa, Foluso O.; Puglisi, Fabio; Gradishar, William J.; Ma, Cynthia X.; Bardia, Aditya; Cristofanilli, Massimo; Davis, Andrew A.
errShare
errSave
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)
errNPJ BREAST CANCER
IF7.6
err2025-01-07
err0
errOAAI
errSpring, Laura M.; Scarpetti, Lauren; Medford, Arielle J.; Niemierko, Andrzej; Comander, Amy; Mulvey, Therese; Schnipper, Lowell; Isakoff, Steven J.; Moy, Beverly; Wander, Seth A.; Shin, Jennifer; Ephrem, Zanta; Laposta, Anneke R.; Denault, Elyssa; Abraham, Elizabeth; Calistro, Gayle; Kalashnikova, Ekaterina; Rodriguez, Angel; Liu, Minetta C.; Aleshin, Alexey; Peppercorn, Jeffrey; Ellisen, Leif W.; Bardia, Aditya
errShare
errSave
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2,-3, and-7 trials
errANNALS OF ONCOLOGY
IF65.4
err2025-01-01
err2
errOAAI
errAndre, F.; Solovieff, N.; Su, F.; Bardia, A.; Neven, P.; Yap, Y. S.; Tripathy, D.; Lu, Y. -S.; Slamon, D.; Chia, S.; Joshi, M.; Chakravartty, A.; Lteif, A.; Taran, T.; Arteaga, C. L.
errShare
errSave
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling
errCANCER LETTERS
IF10.1
err2025-01-01
err0
PREAI
errGerratana, Lorenzo; Davis, Andrew A.; Foffano, Lorenzo; Reduzzi, Carolina; Rossi, Tania; Medford, Arielle; Clifton, Katherine; Shah, Ami N.; Bucheit, Leslie; Velimirovic, Marko; Bandini, Sara; Dai, Charles S.; Wehbe, Firas; Gradishar, William J.; Behdad, Amir; Ulivi, Paola; Ma, Cynthia X.; Puglisi, Fabio; Bardia, Aditya; Cristofanilli, Massimo
errShare
errSave
Immunotherapy for hormone receptor-positive HER2-negative breast cancer
errNPJ BREAST CANCER
IF7.6
err2024-12-06
err0
errOAAI
errCardoso, Fatima; Hirshfield, Kim M.; Kraynyak, Kimberly A.; Tryfonidis, Konstantinos; Bardia, Aditya
errShare
errSave
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
errDRUG RESISTANCE UPDATES
IF21.7
err2024-09-01
err4
errOAAI
errGlaviano, Antonino; Wander, Seth A.; Baird, Richard D.; Yap, Kenneth C. -H.; Lam, Hiu Yan; Toi, Masakazu; Carbone, Daniela; Geoerger, Birgit; Serra, Violeta; Jones, Robert H.; Ngeow, Joanne; Toska, Eneda; Stebbing, Justin; Crasta, Karen; Finn, Richard S.; Diana, Patrizia; Vuina, Karla; de Bruin, Robertus A. M.; Surana, Uttam; Bardia, Aditya; Kumar, Alan Prem
errShare
errSave
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
errNATURE REVIEWS CLINICAL ONCOLOGY
IF82.2
err2024-08-23
err0
PREAI
errLloyd, Maxwell R.; Jhaveri, Komal; Kalinsky, Kevin; Bardia, Aditya; Wander, Seth A.
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
G
Gad Getz
H-index: 248 · Papers: 1.8K
R
Rakesh K. Jain
H-index: 200 · Papers: 1.7K
G
Gabriel N. Hortobágyi
H-index: 187 · Papers: 1.9K
E
Eric P. Winer
H-index: 170 · Papers: 1.6K
M
Martine Piccart
H-index: 149 · Papers: 1.6K
View more